# A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)

> **NCT04770779** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Agios Pharmaceuticals, Inc.** · enrollment: 258 (actual)

## Conditions studied

- Transfusion-dependent Alpha-Thalassemia
- Transfusion-dependent Beta-Thalassemia

## Interventions

- **DRUG:** Placebo Matching Mitapivat
- **DRUG:** Mitapivat

## Key facts

- **NCT ID:** NCT04770779
- **Lead sponsor:** Agios Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-11-30
- **Primary completion:** 2024-04-11
- **Final completion:** 2029-06
- **Target enrollment:** 258 (ACTUAL)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04770779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04770779, "A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04770779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*